Literature DB >> 20509750

Metabolic profiles of difluprednate in rabbit ocular tissues after instillation of difluprednate ophthalmic emulsion.

Tetsuya Tajika1, Hiroaki Takahashi, Yusuke Sakai, Hiroyuki Fujii, Akiharu Isowaki, Hideyuki Sakaki.   

Abstract

Difluprednate (DFBA; 6alpha,9-difluoro-11beta,17,21-trihydroxy-1,4-pregnadiene-3,20-dione 21-acetate 17-butyrate) is an effective anti-inflammatory agent derived from prednisolone. The present study aimed to evaluate the metabolite profile of DFBA in rabbit ocular tissues after instillation of DFBA ophthalmic emulsion. The high-performance liquid chromatography with radiochemical detection was employed to analyze radioactivity in rabbit ocular tissues that had been instilled with a (3)H-DFBA 0.05% ophthalmic emulsion. At 0.5 and 2 h after instillation, DFBA was not detected in the cornea, aqueous humor, or iris/ciliary body. Instead, 21-deacetylated DFBA (DFB), 17-debutylated DFB (DF), and an unknown metabolite were found. The unknown metabolite was identified as de-17-side chain-glucocorticoid metabolite (DF21C), which is a novel glucocorticoid metabolite formed by the scission of the 17-side chain via an unknown metabolic reaction pathway. The K(i) value of DF21C was 5.6 x 10(-7) mol/L, indicating very weak glucocorticoid receptor binding of DF21C (approximately 1000-fold less than that of DFBA and DFB).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20509750     DOI: 10.3109/00498254.2010.490308

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  2 in total

1.  Bioavailability of generic 0.05% difluprednate emulsion in the aqueous humor, cornea, and conjunctiva of New Zealand rabbits after a single dose compared with commercial difluprednate.

Authors:  Arieh Mercado-Sesma; Angélica Contreras-Rubio; Leopoldo Baiza-Durán; Oscar Olvera-Montaño; Mónica Miranda-Robles; José Bonilla-García
Journal:  J Ophthalmic Inflamm Infect       Date:  2017-03-21

2.  Localized alopecia and suppression of hypothalamic-pituitary-adrenal (HPA) axis in dogs following treatment with difluprednate 0.05% ophthalmic emulsion (Durezol®).

Authors:  Katelin Quantz; Amanda L Anderson; Christine D Harman; Erica L Noland; Jacquelyn M Del Valle; Laurence M Occelli; Jessica B Burn; Simon M Petersen-Jones; Daniel K Langlois; Chris G Pirie; Annette D Petersen; András M Komáromy
Journal:  BMC Vet Res       Date:  2021-12-01       Impact factor: 2.741

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.